- Home
- QUBT vs ZYME Comparison
QUBT vs ZYME Comparison
Compare QUBT & ZYME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | QUBT | ZYME |
|---|---|---|
| Founded | 2001 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Manufacturing | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.8B |
| IPO Year | 2019 | 2022 |
Fundamental Metrics
Financial Performance| Metric | QUBT | ZYME |
|---|---|---|
| Price | $6.64 | $25.94 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 11 |
| Target Price | $17.00 | ★ $38.90 |
| AVG Volume (30 Days) | ★ 9.2M | 627.2K |
| Earning Date | 05-14-2026 | 03-02-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 84.93 | 33.33 |
| EPS | ★ N/A | N/A |
| Revenue | $682,000.00 | ★ $105,965,000.00 |
| Revenue This Year | $3,210.56 | $162.82 |
| Revenue Next Year | $51.26 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 82.84 | 38.87 |
| 52 Week Low | $5.76 | $9.03 |
| 52 Week High | $25.84 | $28.49 |
Technical Indicators
Market Signals| Indicator | QUBT | ZYME |
|---|---|---|
| Relative Strength Index (RSI) | 38.83 | 62.74 |
| Support Level | N/A | $22.28 |
| Resistance Level | $7.71 | $27.35 |
| Average True Range (ATR) | 0.43 | 0.94 |
| MACD | 0.00 | 0.17 |
| Stochastic Oscillator | 33.01 | 98.37 |
Price Performance
Historical ComparisonAbout QUBT Quantum Computing Inc.
Quantum Computing Inc is an integrated photonics and quantum optics technology company that provides accessible and affordable quantum machines to the world today. Its products are designed to operate at room temperature and low power at an affordable cost. The Company's portfolio of core technologies and products offer capabilities in the areas of high-performance computing, artificial intelligence, and cybersecurity, as well as remote sensing applications.
About ZYME Zymeworks Inc.
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. It is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.